• Abdulaali R Almutairi, Nimer Alkhatib, Jennifer Martin, Hani M Babiker, Linda L Garland, Ali McBride, and Ivo Abraham.
• Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA; Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ, USA. Electronic address: almutairi@pharmacy.arizona.edu.
• Crit. Rev. Oncol. Hematol. 2019 Oct 1; 142: 16-25.

BackgroundTwo PD-1 (pembrolizumab, nivolumab) and one PD-L1(atezolizumab) inhibitors are approved for previously treated advanced non-small cell lung cancer but have not been compared in head-to-head trials.MethodA network meta-analysis was conducted to compare efficacy/safety of PD-1/PD-L1 inhibitors.ResultsIn five-trials (including long-term updates) with docetaxel as common comparator there were no differences in OS and PFS between PD-1/PD-L1 inhibitors. Pembrolizumab (odds ratio(OR) = 2.22, 95%CrI = 1.28-3.70) and nivolumab (OR = 1.92, 95%CrI = 1.15-3.23) had higher ORRs than atezolizumab and at PD-L1 expression ≥50% and ≥1%. Probabilistically, pembrolizumab ranked first in OS and ORR, and in OS sub-analyses for adenocarcinoma, EGFR-mutant, ECOG-score-1, male, and age <65 years. Nivolumab ranked first in PFS, and in OS sub-analyses for squamous-cell disease, EGFR-wild-type, and ECOG-score-0. Pembrolizumab and nivolumab ranked the best option for most of adverse events.ConclusionWhile pembrolizumab and nivolumab prevailed in rank in OS and ORR benefit, patient characteristics, safety and tolerance should be considered in treatment decision-making.Copyright © 2019 Elsevier B.V. All rights reserved.

38 keywords...

hide…